With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.
Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.
It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses…
Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical…
Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…
Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.
Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.
Heptares Therapeutics has struck a pain drug R&D pact with Daiichi Sankyo.
Galapagos has turned to Pharnext to identify low-doses of approved drugs that boost the efficacy of its pipeline prospects.
Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell.
Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria.